Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety & Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults
Latest Information Update: 10 Jun 2021
At a glance
- Drugs Icatibant (Primary)
- Indications Angioedema
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Shire
- 28 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 15 May 2015 According to the the ClinicalTrials.gov record, planned end date changed from 1 Jul 2015 to 1 Sep 2015.
- 15 May 2015 According to the the ClinicalTrials.gov record, planned primary completion date changed from 1 Jul 2015 to 1 Sep 2015.